DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Germany
  • /
  • Healthcare
Author Program NEWCreate Narrative
AFX logo

Carl Zeiss Meditec AG Stock Price

XTRA:AFX Community·€2.7b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 76 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

AFX Share Price Performance

€30.30
-12.44 (-29.11%)
​
€35.00
Fair Value
€30.30
-12.44 (-29.11%)
13.4% undervalued intrinsic discount
€35.00
Fair Value
Price €30.30
AnalystHighTarget €35.00
AnalystConsensusTarget €27.15
AnalystLowTarget €18.57
Fri, 24 Jul 26
Fair Value€35.00
Share Pricen/a

AFX Community Narratives

AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value €35 13.4% undervalued intrinsic discount

Digital And AI Advances Will Expand Global Eye Care Markets

0users have liked this narrative
0users have commented on this narrative
6users have followed this narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value €27.15 11.6% overvalued intrinsic discount

VISUMAX 800 Approval In China Will Strengthen Future Market Position

1users have liked this narrative
0users have commented on this narrative
33users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value €18.57 63.2% overvalued intrinsic discount

Regulatory Uncertainty And Trade Tensions Will Depress Margins

0users have liked this narrative
0users have commented on this narrative
3users have followed this narrative
AFX logo
Carl Zeiss Meditec
13.4% undervalued intrinsic discount

Digital And AI Advances Will Expand Global Eye Care Markets

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 24 Jul
Read Narrative
AFX logo
Carl Zeiss Meditec
11.6% overvalued intrinsic discount

VISUMAX 800 Approval In China Will Strengthen Future Market Position

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 5 Sep
Read Narrative
AFX logo
Carl Zeiss Meditec
63.2% overvalued intrinsic discount

Regulatory Uncertainty And Trade Tensions Will Depress Margins

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 22 Aug
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
AFX logo

AFX: Earnings Reset Risk From China Headwinds Will Shape Future Prospects

Fair Value: €27.15 11.6% overvalued intrinsic discount
33 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
AFX logo

AFX: China And US Earnings Headwinds Will Constrain Medium Term Repricing

Fair Value: €18.57 63.2% overvalued intrinsic discount
3 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
AFX logo

AFX: Reset Expectations And New Leadership Will Support Future Upside

Fair Value: €35 13.4% undervalued intrinsic discount
6 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Excellent balance sheet, good value and pays a dividend.

1 Risk
2 Rewards
View Full Analysis

Carl Zeiss Meditec AG Key Details

€2.2b

Revenue

€1.1b

Cost of Revenue

€1.1b

Gross Profit

€1.0b

Other Expenses

€121.5m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
Dec 10, 2026
1.39
51.56%
5.57%
27.6%
View Full Analysis

About AFX

Founded
1846
Employees
5798
CEO
Andreas Pecher
WebsiteView website
www.zeiss.com/meditec-ag/de/investor-relations.html?vaURL=www.zeiss.de/meditec-ag/ir

Carl Zeiss Meditec AG operates as a medical technology company in Germany, rest of Europe, North America, and Asia. It operates in two segments, Ophthalmology and Microsurgery. The Ophthalmology segment offers products and solutions for the diagnosis and treatment of chronic eye diseases, including slit lamps, refractometers, and tonometers; optical coherence tomography and fundus cameras for retina examination; functional glaucoma diagnostic devices (perimeters); surgical ophthalmology products comprising surgical microscopes, biometers, and phacoemulsification and vitrectomy equipment; intraocular lenses for cataract surgery; and systems and consumables for laser eye surgery that include the VISUMAX femtosecond laser, which enables minimally invasive correction of vision defects using lenticular extraction, as well as digital products for the storage, analysis, and sharing of clinical data. The Microsurgery segment provides products and solutions for minimally invasive surgical treatments, including surgical visualization, interoperative radiotherapy, interoperative pathology, special surgical instruments, and digital solutions, as well as the ZEISS Tumor Workflow, a cross-product workflow solution. It serves physicians in various fields and hospitals. The company has a strategic collaboration with Envision Health Technologies Inc. to help advance glaucoma care through gamified virtual reality technology. The company was founded in 1846 and is headquartered in Jena, Germany. Carl Zeiss Meditec AG operates as a subsidiary of ZEISS Group.

Recent AFX News & Updates

User avatar
Narrative Update • Sep 05

AFX: Earnings Reset Risk From China Headwinds Will Shape Future Prospects

Carl Zeiss Meditec's analyst price target has been revised lower from about €28.63 to €27.15, as analysts factor in softer revenue growth, slightly lower profit margins, and a lower future P/E multiple, alongside recent price target cuts that cite earnings headwinds in China and the U.S. and rising competitive pressures. Analyst Commentary Recent research on Carl Zeiss Meditec has turned more cautious, with several firms revising price targets lower and expressing concern about earnings pressure in key markets.

Recent updates

No updates

Carl Zeiss Meditec AG Competitors

FME logo

Fresenius Medical Care

Symbol: XTRA:FME
Market cap: €10.2b
OBCK logo

Ottobock SE KGaA

Symbol: XTRA:OBCK
Market cap: €3.6b
COP logo

CompuGroup Medical SE KGaA

Symbol: HMSE:COP
Market cap: €1.4b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide